Why the FDA's Approval of Opill Matters--And What's Next
July 14, 2023
July 14, 2023
BALTIMORE, Maryland, July 14 -- Johns Hopkins University's Bloomberg School of Public Health issued the following news release:
By Melissa Hartman, associate director of editorial at the Johns Hopkins Bloomberg School of Public Health
Fifty years ago, the oral contraceptive medication norgestrel was FDA-approved for prescription use. Today, the FDA approved Opill, a brand-name version of this drug, for over-the-counter sale--giving millions of people access to safe . . .
By Melissa Hartman, associate director of editorial at the Johns Hopkins Bloomberg School of Public Health
Fifty years ago, the oral contraceptive medication norgestrel was FDA-approved for prescription use. Today, the FDA approved Opill, a brand-name version of this drug, for over-the-counter sale--giving millions of people access to safe . . .